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ATP consumptionATP provided by oxidative phosphorylation supports highly complex and energetically expensive cellular
processes. Yet, in several pathological settings, mitochondria could revert to ATP consumption, aggravating
an existing cellular pathology. Here we review (i) the pathological conditions leading to ATP hydrolysis by
the reverse operation of the mitochondrial FoF1-ATPase, (ii) molecular and thermodynamic factors
inﬂuencing the directionality of the FoF1-ATPase, (iii) the role of the adenine nucleotide translocase as the
intermediary adenine nucleotide ﬂux pathway between the cytosol and the mitochondrial matrix when
mitochondria become ATP consumers, (iv) the role of the permeability transition pore in bypassing the ANT,
thereby allowing the ﬂux of ATP directly to the hydrolyzing FoF1-ATPase, (v) the impact of the permeability
transition pore on glycolytic ATP production, and (vi) endogenous and exogenous interventions for limiting
ATP hydrolysis by the mitochondrial FoF1-ATPase.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
It is now a textbook fact that the most important and fundamental
function of mitochondria is (i) to provide ATP for cellular functions,
(ii) to participate in the Ca2+ homeostasis, and (iii) to generate and
eliminate reactive oxygen species (ROS). In addition, mitochondria
could integrate and release lethal signals leading to cell death. ATP
provision and Ca2+ uptake/release are essential physiological func-
tions in brain mitochondria. Compelling evidence have accumulated
in the last two decades demonstrating that impaired mitochondrial
function is involved in cellular deterioration associated with patho-
logical settings such as ischemia/reperfusion [44], excitotoxicity
[110], neurodegenerative diseases, or trauma [49]. Since the key
features of mitochondria are inherently connected, impaired mito-
chondrial function usually involves energy deﬁcit, impaired Ca2+
homeostasis, as well as oxidative stress [15]. The latter describes the
imbalance of production/elimination of ROS leading to accumulation
of these toxic species. In this review, we are focusing on the energy
deﬁcit related to pathological settings, in which mitochondria not
only fail to produce ATP but function as ATP consumers.
In intact mitochondria, the electron ﬂow through the respiratory
chain generates the proton electrochemical gradient (or protonmo-
tive force, pmf; in mV), whose major component is the membrane
potential (ΔΨm) being in the range of 150-180 mV, inside negative.
pmf drives the ATP hydrolyzing F0F1-ATPase to function as ATP
synthase and promotes the phosphorylation of ADP to ATP. However,
in mitochondria having an impaired respiration or leaky inner
membrane, the F0F1-ATPase reverses and, at the expense of ATP361 2670031.
m-Vizi).
ll rights reserved.hydrolysis, contributes to the maintenance of ΔΨm at a suboptimal
level by pumping protons out of the matrix. It is obvious that
persistent operation of F0F1-ATPase in reverse could consume the
cellular ATP reserves driving the cell into an energy crises eventually
leading to cell demise [96]. Likewise, when the condition involving
reverse operation of F0F1-ATPase is further complicated by an
increased ATP demand, the cellular deterioration is accelerated.
The contribution of mitochondria to cell death has been subject of
an intense research for the past two decades. In response to a variety
of stressful stimuli, a number of molecules have been identiﬁed to
emanate from mitochondria, such as cytochrome c, Smac/Diablo,
endonuclease G, AIF to name a few, promoting apoptotic cell death
[28,36,84,123,130]. The ability of mitochondria to harbor such an
abundance of death-signaling molecules led them to be likened to
“Pandora's box” [136].
However, although the list of mitochondrial intermembrane
proteins triggering apoptosis when released into the cytosol is
expanding [68,123,128], hard evidence of apoptotic cell death in
vivo in the adult CNS under pathological conditions such as focal/
global ischemia, neurodegeneration, or trauma, are lacking
[55,85,92,129]. On the other hand, evidence that mitochondrial
dysfunction is associated with necrotic cell death is ample
[23,45,46,98,122,127]. The concept of “energy availability” or even
more naively “ATP availability” has been proposed to serve as the
switch between apoptosis and necrosis [80,134]. Based on the
property of dysfunctional mitochondria to release death-signaling
molecules, as well as to be capable of mounting intense ATP
hydrolysis, their pivotal role in dictating the type of cell death was
quickly realized [98,102].
For intactmitochondrial functions, the integrity of themitochondrial
membranes is critical; mitochondria having leaky inner membrane
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reasons that are incompletely understood, mitochondria possess
intrinsic mechanisms for disrupting membrane integrity by recruiting
speciﬁc proteins to form a pore across the two membranes. This pore,
termed “permeability transition pore” (PTP) [60,65,66], is of a
sufﬁcient size (cut-off ∼1.5 kDa) to allow the uncontrollable passage
of solutes and water that results in swelling and ultimately rupture of
the outer membrane since the mitochondrial matrix is hyperosmolar
to the cytosol. The identity of the proteins comprising the PTP is
debated; the voltage-dependent anion channel (VDAC), hexokinase
(HK), creatine kinase (CK), the mitochondrial peripheral benzodiaz-
epine receptor (mPBR), the adenine nucleotide translocase (ANT), the
cyclophilin D (cypD), and more recently the phosphate carrier [81],
have all been proposed to participate in the formation of the pore [48].
Cyclophilin D is a member of the cyclophilins family [135] that
exhibit peptidyl-prolyl cis/trans isomerase activity (PPI) and as such
it could mediate, in theory, the folding of proteins to the desired
conformation in order for the pore to materialize [61].
Unequivocal evidence showing that cyclophilin D plays a major
role in the manifestation of necrotic cell death was provided by
genetically engineering cyclophilin D knockout mice (cypD KO)
[3,8,91,119], which were more resistant to necrotic stimuli than the
wild-type (WT) littermates. From the studies using cypD KO mice,
cyclophilin D emerged as an important drug target, something that is
being currently exploited in several clinical trials due to the
availability of high-afﬁnity ligands [87]. A fairly obvious reason why
maintenance of mitochondrial integrity (through inhibition of the
cyclophilin D-dependent PTP) is beneﬁcial to the fate of cell is that
mitochondria may not become consumers of cytosolic ATP.
2. ATP consumption by mitochondria under conditions associated
with neurodegeneration
The question arises: what are the conditions that favor the ATP
hydrolysis by mitochondria and are relevant to neurodegeneration.
The exact molecular mechanism behind neurodegeneration and the
sequence of events leading to cell death in the central nervous system
are still unknown despite intensive research in the last decades.
However compelling evidence support the role of mitochondria in the
pathogenesis of a host of neurodegenerative diseases [2,9,27,82].
Oxidative stress and respiratory failure are common features in the
pathology of these conditions (reviewed recently by Chaturvedi and
Beal [20]), shifting mitochondria toward consuming rather than
synthesizing ATP.
Decreased activity of Complex I, the ﬁrst complex in the
mitochondrial respiratory chain, was found in autopsy samples of
the substantia nigra [118] and frontal cortex [105] from patients who
suffered from Parkinson's disease (PD). The involvement of complex I
deﬁciency in PD became evident with the discovery that systemic
administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) produces parkinsonian syndromes by selectively inhibiting
complex I of the respiratory chain [16,47,79]. Parkinsonian pheno-
types were also reproduced in laboratory animals with infusion of the
well-known complex I inhibitor, rotenone [12]. When the respiratory
chain is inhibited, ΔΨmwould decrease and to prevent this, the F0F1-
ATPase starts to function as a proton pump and hydrolyses ATP
[96,121]. Even with nearly complete inhibition of complex I by
rotenone, ΔΨm is maintained [24] or only partially depolarized [121]
in in situ mitochondria of isolated nerve terminals (synaptosomes)
but collapses in the presence of oligomycin, inhibitor of the F0F1-
ATPase, clearly demonstrating the role of F0F1-ATPase in the
maintenance of ΔΨm [24,121]. Glycolysis is the major source of ATP
under this condition and as long as this is sufﬁcient to maintain the
ATP-dependent functions, primarily the Na+/K+-ATPase of the
plasma membrane, and the ATP hydrolysis by the F0F1-ATPase,
ΔΨm is not collapsed, the cellular ATP pool is not depleted, andcells survive. Glycolytic ATP generation can be accelerated 10-fold in
nerve terminals when oxidative phosphorylation is abolished and as a
result, ATP/ADP ratio decreases by ∼70 % but not collapses [24].
Survival of cells with impaired respiratory chain in vivo likely depends
on the glycolytic capacity; at least that is indicated by studies with
cultured cells, where some cell types having high glycolytic capacity
can be maintained for hours while others show severe energetic
insufﬁciency in the presence of respiratory inhibitors (reviewed in
reference [96]).
Complex I was only partially inhibited in PD patients (∼30%) but
that degree of inhibition was sufﬁcient to decrease the ATP level in
nerve terminals [31,32], suggesting a high ﬂux control of the
respiratory chain by complex I in nerve terminals. It has also been
demonstrated that when complex I is inhibited by 25%, the F0F1-
ATPase already reverses and supports the maintenance of ΔΨm in
isolated nerve terminals [22].
Oxidative stress is another factor, which could contribute to the
reversal of the F0F1-ATPase under pathological conditions relevant to
neurodegeneration. Several lines of evidence support the role of
oxidative stress in the pathology of neurodegenerative diseases,
which have been reviewed recently by Lin and Beal [82] and
Henchcliffe and Beal [63]. Oxidative damage is an early event in the
pathology of Alzheimer's disease (AD) [100], which precedes
amyloid-β-peptide deposition in AD animal models [107]. Increased
ROS levels were found in AD transgenic mice prior to the appearance
of plaques [86]. Signs of oxidative damage were also found in autopsy
brain samples from PD patients, such as lipid peroxidation, DNA and
RNA damage [33,137], and oxidative stress has been linked to Lewy
body formation [69].
Wide range of effects of oxidative stress on mitochondria have
been found in in vitro experiments. Relevant to the topic of this
review is the report that oxidative stress alone induced by H2O2 were
without an effect onΔΨmof in situ synaptic mitochondria, but greatly
reduced ΔΨm in the presence of oligomycin clearly showing that
under oxidative stress ΔΨm is maintained by the reverse operation of
the F0F1-ATPase [24]. Various oxidants were also reported to enhance
glutamate-induced mitochondrial depolarization [117]. ROS are
unlikely to limit directly the mitochondrial respiration as individual
components of the respiratory chain are relatively resistant to
oxidants [67,138]; however, they can limit NADH generation [125]
due to inhibition of α-ketoglutarate dehydrogenase, a key Krebs cycle
enzyme [104,125]. It is of note that the activity of this enzyme was
found to be greatly reduced in postmortem brain samples of patients
who have suffered from AD [17,54] or PD [89,90]. In addition, the
enzyme is sensitive to inhibition by β-amyloid [19].
A further important aspect of oxidative stress, which is relevant
to neurodegeneration, in particular to PD, is that ΔΨm collapses
when the oxidative burden is combined with complex I inhibition,
while either of these insults themselves inﬂuence ΔΨm [22]. The
underlying mechanism is likely the inhibition of glyceraldehydes-3-
phosphate dehydrogenase by ROS [67,83], resulting in a limited ATP
generation in glycolysis. Consistent with this, H2O2 was found to
decrease the ATP/ADP ratio in isolated nerve terminals even in the
presence of an uncoupler [126], a condition when the accelerated
glycolysis provides ATP for the ATP hydrolysis by the reversed F0F1-
ATPase [1,121]. As emphasized above and reviewed elsewhere
[96], glycolytic ATP generation becomes critical when complex I is
inhibited and ΔΨm is maintained by the reverse function of the F0F1-
ATPase.
The repercussions of a bioenergetic insufﬁciency caused by
mitochondrial ATP consumption have been examined in a variety of
contexts using brain tissue andwere reported to result in an enhanced
Ca2+ entry via the plasma membrane [1,97], an increased neurotoxic
effect of glutamate [64,99], a progressive deregulation of Ca2+ and
Na+ homeostasis [25]. The role of the plasmalemmal Na+/K+ATPase,
as the major ATP-utilizing reaction in neurons [121], and that of the
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the loss of the Na+ and Ca2+ homeostasis. Deregulation of Na+ and
Ca2+ homeostasis is a key element in initiating/propagating neuronal
damage, which is best characterized for glutamate excitotoxicity
[30,35].
It is to note that an increased ATP demand in combination with
conditions involving ATP consumption by mitochondria could be fatal
for cells. Severe bioenergetic failure developed in glutathione-
depleted cerebellar granule neurons when the oxidative burden was
combined with an increased cytoplasmic ATP demand imposed either
by sustained plasma membrane depolarization or by the excitotoxin
kainate [131]. Similarly, oxidative stress combined with a cytoplasmic
Na+ load resulted in ATP depletion, loss of ΔΨm and Na+ and Ca2+
deregulation in nerve terminals [25]. For glutamate excitotoxicity, it
has been documented by Nicholls and colleagues, using state-of-the-
art in situ bioenergetic approaches that Na+ and Ca2+ load imposes
such a large energetic demand on cells that the entire respiratory
capacity of in situmitochondria is used [95]. As a result, even amodest
restriction in mitochondrial capacity due to a diminished complex I
activity, such as that observed in models of Parkinson's disease, or
preexisting oxidative stress implicated in a variety of neurodegener-
ative diseases, greatly potentiate glutamate excitotoxicity, and
commit the cell to die [95,112].3. Factors determining the ATP consumption by mitochondria
In isolation, the mitochondrial FoF1-ATPase vigorously hydrolyzes
ATP [50]. This molecular rotor forms ATP only when there is sufﬁcient
pmf across the membrane in which it is embedded. Ultimately, this
depends on the concentration of the reactants participating in the ATP
formation/hydrolysis process, namely, free matrix [ADP], free matrix
[Pi], free matrix [ATP], matrix pH and intermembrane space pH, as
well as the H+/ATP ratio (coupling ratio “n” [29,124]). The rate as well
as the directionality of the FoF1-ATPase operation is dictated by the
magnitude of the pmf. However, the mechanisms by which the FoF1-
ATPase operate and reverse are not fully understood. It is unclear
whether the reverse operation of the ATPase is a mirror image of the
forward mode, or it follows a different path [50,133]. Whatever the
exact mechanism of ATP synthesis/hydrolysis may be, a plethora of
cytosolic and mitochondrial ATP-consuming processes beneﬁt from
the high ATP provision by the synthesis operation of the FoF1-ATPase,
provided that pmf is of sufﬁcient magnitude. At 37 °C, pmf=ΔΨm −
60ΔpH, where ΔpH is the pH gradient across the inner mitochondrial
membrane, which could be in the range of 0.8–0 and is dependent on
the concentration of matrix Pi [26,75]. ΔΨm and ΔpH are far from
being static values, even during physiological conditions. At least for
ΔΨm, it has been shown that mitochondria in a cell exhibit signiﬁcant
ﬂuctuations, some greater than 100 mV [37,53,101]. This phenome-
non, termed “ΔΨm ﬂickering” is observed in mitochondria probed in
isolation or in situ [101]. Quantitative measurements of ΔΨm and/or
ΔpH during stressful stimuli in situ are scarce [13,94], while some
indirect indices of metabolic competence may be misleading [14]; for
example, mitochondrial Ca2+ uptake is electrophoretic in nature;
however, mitochondria could sequester Ca2+ even when they are
depolarized to less than 10% of their full attainable ΔΨm [26]. When
mitochondria are dysfunctional, respiration is impaired or mitochon-
dria are uncoupled, but the inner membrane permeability remains
uncompromised, the extent of pmf, hence of ΔΨm and ΔpH, would
dictate whether FoF1-ATPase generates or consumes ATP. The way in
which the participating reactants (see above) contribute to this is yet
to be determined. Recently, there is a ﬂare in modeling approaches
using the reactants as parameters in an attempt to predict
mitochondrial bioenergetics [4,5,10,11,38]. Using such models, it
would be one day possible to predict if FoF1-ATPase operates in the
forward or reverse mode during predeﬁned metabolic conditions.What is the source of ATP for the FoF1-ATPase operating in reverse
with uncompromised inner mitochondrial membrane? As discussed
above glycolysis is thought to provide ATP for the FoF1-ATPase to
hydrolyze and since hydrolysis takes place on the matrix side, both
adenine nucleotide translocase (ANT) and FoF1-ATPase must operate
in reverse when mitochondria consume cytosolic ATP. However, the
operations of ANT and of the FoF1-ATPase are not necessarily in
directional synchrony; these molecular entities only share matrix
[ADP] and [ATP] as common reactants. Cytosolic [ADP] and [ATP]
participate in the ANT operation, but not in the reaction catalyzed by
the FoF1-ATPase. By the same token, while matrix [Pi], matrix pH and
intermembrane space pH, as well as the H+/ATP ratio dictate the rate
and directionality of the FoF1-ATPase, they are not involved directly in
the ANT reaction. Therefore, ﬂuctuation in the concentration of
parameters that have no direct inﬂuence on the ANT or FoF1-ATPase
may result in reversal of one but not that of the other. There are some
reports in the literature that suggest a physical link of the FoF1-ATPase
to the ANT, that together with the phosphate carrier would form a so-
called ATP synthasome, (ATPase:Pi transporter:ANT in 1:1:1 ratio)
[21,76,106]. However, that is at odds with an estimated ratio of ANT/
Pi-transporter of ∼4; for details on this matter, the reader is referred
to a recent review by Martin Klingenberg [74].
From the above considerations, it is apparent that certain values of
ΔΨm and/or ΔpH may allow only the ANT but not the FoF1-ATPase to
reverse, and vice versa, i.e., the FoF1-ATPase to reverse but not the
ANT. Furthermore, the reverse operation of the FoF1-ATPase is subject
to regulation, at least in tissues expressing the endogenous IF-1
protein (see below), but for the ANT no ligand-mediated regulation
has been described so far. It is therefore fair to assume that there is no
directional synchrony in the operation of ANT and FoF1-ATPase.
Therefore, it is intriguing to consider that ATP generated by substrate-
level phosphorylationwithin thematrixmight supply ATP to the FoF1-
ATPase. Two reactions are capable of substrate-level phosphorylation:
the mitochondrial phosphoenolpyruvate carboxykinase (PEPCK) and
the succinate-CoA ligase (SUCL or succinate thiokinase or succinyl-
CoA synthetase). Mitochondrial PEPCK, by its reverse reaction forming
phosphoenolpyruvate and using GTP, has been proposed to partici-
pate in the transfer of the phosphorylation potential from mitochon-
dria to cytosol [78]. SUCL catalyzes the reversible conversion of
succinyl-CoA and ADP or GDP to CoASH, succinate and ATP or GTP
[71]. The enzyme is a heterodimer, being composed of an invariant α
subunit encoded by the gene SUCLG1, and a substrate-speciﬁc β
subunit, encoded by either SUCLA2 or SUCLG2. This dimer combination
results in either an ADP-forming SUCL (A-SUCL, EC 6.2.1.5) or a GDP-
forming SUCL (G-SUCL, EC 6.2.1.4). The β subunit thus determines the
substrate speciﬁcity of the enzyme. Both β subunits are widely
expressed, with SUCLG2 predominantly expressed in anabolic tissues
such as liver, and SUCLA2 in catabolic tissues such as brain and skeletal
muscle [71,72,78]. SUCLG1 is ubiquitously expressed [78]. Therefore,
it is possible that the availability of succinyl-CoA for the succinyl-CoA
ligase in ailing brain mitochondria would determine whether matrix
substrate-level phosphorylation could provide ATP for FoF1-ATPase
working in reverse.
4. The role of ANT as the intermediary adenine nucleotide ﬂux
pathway between the cytosol and the mitochondrial matrix
Theoretically, the rate of ATP provision to the FoF1-ATPase would
be the sum of the rate of matrix substrate-level phosphorylation and
that by which ATP is supplied by the operation of the ANT. The rate
and directionality of the reactions in the citric acid cycle would
determine the rate of production of ATP by SUCL. Likewise, the rate of
ATP inﬂux into the matrix depends both on the rate of production in
glycolysis and on the rate of transport by the ANT. The contribution of
citric acid cycle to ATP production by SUCL and the regulation of the
rate of ATP production by glycolysis is beyond the scope of this review.
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lated due to Pasteur effect, ANT becomes the intermediary entity
between cytosolic ATP provision and the consuming FoF1-ATPase. The
maximum turnover number (deﬁned as the maximum number of
substrate molecules that an enzyme can convert to product per
catalytic site per unit of time) of FoF1-ATPase is approximately 50–
100 s-1 [50,108]. The maximum turnover number of ANT in the
forward mode is in the range of 6–99 s-1, depending on isoform
distribution, among other conditions [26]. Regarding the reverse
mode of the ANT, there are few reports in the literature [74] esti-
mating turnover numbers in a relevant range, although mathematical
modeling of the ANT in isolation predicts almost double rates [88].
Assuming that the rate of ATP inﬂux by the ANT may be equal or
slower than the rate of ATP hydrolysis by the FoF1-ATPase, the ANT
may become limiting if the amount of ANTs present in mitochondria
is equal or lower than that of the FoF1-ATPase. The possible limitation
by ANT imposed on the consuming FoF1-ATPase is not to be confused
with the higher “ﬂux control coefﬁcient” of the ANT than that of the
FoF1-ATPase; the ﬂux control coefﬁcient is deﬁned (for inﬁnitesimally
small changes) as the percentage change in the steady state rate of
the pathway divided by the percentage change in the enzyme level
causing the ﬂux change. ANT exhibits a large ﬂux control coefﬁcient
[73]; however, this has been deﬁned for the rate of oxygen
consumption, not for ATP formation or hydrolysis by the FoF1-ATPase.
Considering the above, we propose that in the absence of matrix
substrate-level phosphorylation, ANT gains a critical role in conveying
ATP into the matrix at a sufﬁcient rate for the FoF1-ATPase to
hydrolyze. Since pertaining metabolic conditions as well as ANT iso-
form distribution play a major role in the turnover number of ANT
[26], it follows that the very same conditions are able to affect the rate
of ATP hydrolysis by the FoF1-ATPase.
5. The role of PTP in mitochondrial ATP consumption
So far, we have considered factors that are important for ATP
consumption by mitochondria having impaired respiration but
uncompromised inner membrane permeability. Next, we address
the role of PTP as (i) a bypass of ANT, allowing the delivery of cytosolic
ATP directly to the consuming FoF1-ATPase, and (ii) an impediment to
glycolytic ATP production.
As mentioned above, PTP is of a sufﬁcient size (cutoff ∼1.5 kDa) to
allow the uncontrollable passage of solutes and water across the inner
mitochondrial membrane, resulting in cell death as observed in
neurodegeneration [49]. Equally ﬁt, interactions of Bax and tBid with
VDAC [6,7] or Bax alone [120] also lead to formation of pores with
mega-conductances. Pore opening in mitochondria would obviously
lead to a collapse of ΔΨm and ΔpH and to full reversal of the FoF1-
ATPase, with a direct access to cytosolic ATP. This has the following
two ramiﬁcations: (i) ANT no longer controls ATP hydrolysis by the
FoF1-ATPase and (ii) ADP and Pi, the hydrolysis products of the FoF1-
ATPase, are diluted in the cytosol–matrix continuum; therefore, the
impediment of the reversal of FoF1-ATPase, which is otherwise
exerted by ADP and Pi, is lost [57]. A secondary consequence of
chaotropic ADP and Pi production in the cytosol–matrix continuum
may be that ADP is no longer available at sites where it could
stimulate glycolysis. Although at present this statement is purely
speculative, the apposition of mitochondria to other organelles for the
sake of optimal operation is a well-established phenomenon [37,111].
ADP is known to accumulate in the intermembrane space resulting in
steep gradients across the outer mitochondrial membrane, playing a
signiﬁcant role in efﬁcient oxidative phosphorylation [51,52]. In
addition, the “wiring” of mitochondrial ATP production to nuclear
utilization has been also described [39,40], involving the concerted
action of adenylate kinase, nucleoside diphosphate kinase, and
creatine kinase. Finally, matrix adenine nucleotide microcompart-
mentation has been proposed [58,103,132], although never unequi-vocally proven [59,62]. It is therefore highly probable that
compartmentalized provision of ADP to the cytosol may assist in the
stimulation of glycolysis partially compensating for the impaired
mitochondrial ATP generation in ATP-consuming mitochondria.
Besides the above speculation, there are two phenomena that are
highly likely to counteract the stimulation of glycolysis, when
mitochondria experience PTP: (i) the spill of citrate from mitochon-
dria to the cytosol, which is well known to play a major role in the
regulation of glycolysis by inhibiting phosphofructkinase-1 and (ii)
the depletion of NAD+ [34], which is otherwise required for the
glyceraldehyde-3-phosphate dehydrogenase reaction. Due to opening
of PTP, NAD+ leaks from the matrix to the cytosol, where a
mitochondria-associated NAD+-glycohydrolase degrades it to as low
as 92% of the original values [34]. The remaining 8% [NAD+] is likely to
be insufﬁcient for glyceraldehyde-3-phosphate dehydrogenase reac-
tion. The additional contribution of the catabolic products of this
NAD+-glycohydrolase to cell demise has been reviewed elsewhere
[23]. It is to note here that loss of pyridine nucleotides from mito-
chondria is also crucial in our recent ﬁnding, showing that in isolated
mitochondria exhibiting PTP, the production of ROS is not increased, as
expected, but rather decreased by Ca2+ [77]. Finally, it has also been
proposed that a diminished provision of ATP for hexokinase may limit
phosphorylation of glucose upon entry to the cytosol, thereby
impeding glycolytic ﬂux at its most proximal step [41]. Therefore, in
the presence of PTP, a diminished glucose phosphorylation, a
decreased glyceraldehyde-3-phosphate dehydrogenase ﬂux, and an
impaired PFK-1 activation could collectively lead to a spiral toward
decreased ATP production by the glycolysis.
6. Interventions for limiting mitochondrial ATP hydrolysis
With the exception of a recently discovered possible phosphory-
lation site [42], ANT does not appear to be subject to ligand or
allosteric type of regulation. However, nature has developed at least
one mechanism for preventing overconsumption of ATP by the FoF1-
ATPase, during extensive mitochondrial depolarization, substantiated
by the IF-1 protein [18,109]. IF-1 was discovered in 1963 by Pullman
and Monroy as a soluble, heat-stable protein present in bovine heart
mitochondria, that inhibited the ATP hydrolase activity of the FoF1-
ATPase [109]. Several additional mechanisms of regulation of ATPase
are known to exist [43,57,93]; however, they are not as well
characterized as IF-1 [57]. IF-1 exhibits strong tissue and species
distribution, and also variable level of expression and afﬁnity for the
FoF1-ATPase [114–116]. The contribution of IF-1 in neurodegeneration
has not been addressed; nonetheless, the possible beneﬁt from the
existence of this molecule is reﬂected in the fact that during
myocardial ischemia, 90% of the total ATP content could be
inefﬁciently hydrolyzed, which can be diminished to less than 50%
due to inhibition of the reverse operation of FoF1-ATPase by IF-1
[56,70,113]. Furthermore, it was recently demonstrated that over-
expression of IF-1 is protective against ischemic injury [18]. What is
rather surprising is that the inhibition of FoF1-ATPase by IF-1 is
incomplete [56], thereby mitochondrial and cytosolic ATP pools are
not completely rescued. Mindful of this oddity, Grover and colleagues
have generated a synthetic FoF1-ATPase inhibitor, called BMS-199264,
that affects only the reverse operation [56,57]. Accordingly, BMS-
199264 was shown to be strongly cardioprotective in ischemia/
reperfusion paradigms, without affecting ATP synthesis [57].
7. Conclusions
The multitude of cytosolic as well as matrix ATP-consuming pro-
cesses, all dependent on the provision of ATP by oxidative phosphory-
lation, attest to the complexity of eukaryotic life. However, besides
some important differences regarding the integrity of the inner
mitochondrial membrane, it remained an inherent ability of mito-
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stress. This is probably one of the best examples of familiar
knowledge: what can make you, can also break you.
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